Donna Senger

Donna Senger is a Senior Investigator at the Lady Davis Institute for Medical Research, an Associate Professor in the Gerald Bronfman Department of Oncology at McGill University, and a founding scientist of Arch Cancer Therapeutics, a subsidiary of Arch Biopartners.

Professor Senger has had a long-standing interest on the development of pediatric and adult central nervous system (CNS) tumours including defining the molecular characteristics of invasive glioma, investigating cancer stem cells as therapeutic targets and understanding how the brain microenvironment impacts treatment.

More recently Pr. Senger’s research has focused on mechanisms important for the development of organ selective cancer metastasis, establishing in vivo cancer models for preclinical testing and identification and implementation of therapeutics for the treatment of sarcoma and metastatic melanoma.